{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-24-000078","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.429194+00:00","generated_at":"2026-06-01T04:20:33.702812+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Editas reni-cel RUBY trial: 18 SCD patients VOE-free; EdiTHAL: 7 TDT patients transfusion-free","bullets":["18 SCD patients free of vaso-occlusive events post-reni-cel (follow-up 2.4-22.8 months); mean total Hb >14 g/dL, HbF >40%.","7 TDT patients transfusion-free for 4.1-12.8 months; mean total Hb 12.1 g/dL at month 6, HbF 10.9 g/dL.","No serious adverse events related to reni-cel in either trial; safety profile consistent with myeloablative conditioning.","Median neutrophil engraftment 23 days (SCD and TDT); platelet engraftment 24 days (SCD), 38 days (TDT).","Further clinical update from both trials expected by year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-24-000078","json":"https://secwatch.observer/filing/0001650664-24-000078.json","markdown":"https://secwatch.observer/filing/0001650664-24-000078.md","text":"https://secwatch.observer/filing/0001650664-24-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000078/0001650664-24-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000078/edit-20240614.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:20:33.702812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}